Description
LuciAda 200mg is a film-coated oral tablet containing Adagrasib 200 mg, manufactured by Lucius Pharmaceutical Co., Ltd., Vientiane, Laos (WHO-GMP certified). It is a first-in-class, oral, selective KRAS G12C inhibitor used to treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received at least one prior systemic therapy. It is also approved in combination with cetuximab for KRAS G12C-mutated metastatic colorectal cancer (CRC).
LuciAda contains the same active ingredient as Krazati® (Bristol-Myers Squibb / Mirati Therapeutics), which received US FDA accelerated approval in December 2022 for NSCLC and in June 2024 for colorectal cancer.
How LuciAda 200mg Works
Adagrasib is a selective, irreversible inhibitor of the KRAS G12C mutation — a specific genetic alteration that drives uncontrolled cell growth in certain cancers. It permanently locks the mutated KRAS protein in its inactive state by covalently binding to the cysteine residue at position 12, blocking downstream signaling pathways (MAPK and PI3K) that cancer cells rely on to survive and multiply. This precise mechanism spares normal cells, offering a personalized treatment with less collateral damage than traditional chemotherapy. Read the official FDA approval notice for adagrasib.
Uses
LuciAda 200mg is prescribed for:
- KRAS G12C-mutated locally advanced or metastatic NSCLC in adults who have received at least one prior systemic therapy (confirmed by an FDA-approved test)
- KRAS G12C-mutated metastatic colorectal cancer (CRC) — in combination with cetuximab — after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy
- Other KRAS G12C-mutated solid tumors as identified in clinical settings
A confirmed KRAS G12C mutation diagnosis is required before treatment begins.
Dosage
| Detail | Information |
|---|---|
| Recommended dose | 600 mg (three 200 mg tablets) orally twice daily — 1,200 mg/day total |
| Administration | Swallow tablets whole, with or without food |
| Important | Do not crush, chew, or split tablets |
| Duration | Continue until disease progression or unacceptable toxicity |
| Dose adjustments | Stepwise reduction (600 mg → 400 mg → 300 mg twice daily) for adverse reactions |
| Missed dose / vomiting | Skip it; take the next dose at the scheduled time — do not double up |
Always follow your oncologist’s prescription. Full prescribing details are in the official FDA label for Krazati (adagrasib). Storage: keep in a dry place at 20–25°C, away from light and out of reach of children.
Side Effects
Common (≥20%): diarrhea, nausea, vomiting, fatigue, musculoskeletal pain, edema, decreased appetite, cough, dizziness, constipation, abdominal pain.
Common laboratory changes: raised liver enzymes (AST/ALT), increased creatinine, low sodium, low hemoglobin, low lymphocyte/platelet/magnesium/potassium, increased lipase.
Serious (seek medical help immediately): liver toxicity, lung inflammation (interstitial lung disease/pneumonitis), kidney impairment, QTc interval prolongation (heart rhythm changes), severe gastrointestinal events.
ECG and electrolyte monitoring is recommended before and during treatment due to QT prolongation risk. Liver and kidney function should be checked regularly. Avoid medicines that further prolong the QT interval where possible.
FAQ
What is LuciAda 200mg used for?
LuciAda 200mg is used to treat adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) after at least one prior therapy, and KRAS G12C-mutated metastatic colorectal cancer in combination with cetuximab.
Is LuciAda the same as Krazati?
Yes. Both contain Adagrasib as the active ingredient. LuciAda is the Lucius Pharmaceutical (Laos) version of Krazati®.
How many tablets of LuciAda 200mg do I take?
The recommended dose is 600 mg twice daily — that is three 200 mg tablets in the morning and three in the evening (six tablets per day), with or without food.
Do I need a test before starting?
Yes. A confirmed KRAS G12C mutation must be detected via an FDA-approved companion diagnostic test (such as the QIAGEN therascreen KRAS RGQ PCR kit for tissue or the Agilent Resolution ctDx FIRST Assay for plasma).
Can LuciAda be taken with food?
Yes. LuciAda can be taken with or without food. Take it at approximately the same times each day for consistency.
What is the most common side effect?
Diarrhea, nausea, and vomiting are the most common. Most are mild to moderate and manageable with supportive care — speak to your doctor if symptoms are severe or persistent.
Why is heart monitoring needed?
Adagrasib can prolong the QTc interval (a measure of heart electrical activity), which may cause abnormal heart rhythms. Your doctor will perform ECGs and check electrolytes (potassium, magnesium) before and during treatment.
Can the dose be reduced for side effects?
Yes. The dose can be reduced in steps from 600 mg → 400 mg → 300 mg twice daily. Do not adjust the dose yourself — always consult your oncologist.
Is it safe during pregnancy?
No. Adagrasib can cause harm to an unborn baby. Effective contraception should be used during treatment and for a period after the last dose. Do not breastfeed during treatment. Discuss specifics with your doctor.
How should it be stored?
In a dry place at 20–25°C, away from light, and out of reach of children.
Reviews
There are no reviews yet.